Patients With HCV, Chronic Kidney Disease Less Likely to Receive Antivirals
Individuals with CKD and HCV infection achieve high cure rates with newer anti-HCV treatment regiments.
A study sought to examine whether successful treatment of hepatitis C virus with direct-acting antivirals translates into decreased mortality risk in patients without significant liver disease.
The absolute risk of hepatitis B virus reactivation in individuals with active or resolved infections who were treated with DAAs for hepatitis C virus.
A minimal decrease in eGFR was found in patients with chronic hepatitis C taking oral direct-acting antiviral agents.